Kyntra Bio, Inc.
KYNBHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeKyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. With a market capitalization of $18.2M, it sits in micro-cap territory. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Market Cap
$18.2M
Beta
1.05
P/E (TTM)
—
P/E (Fwd)
-0.32
EPS (TTM)
$-7.31
EPS (Fwd)
$-14.23
ROE
—
ROA
-22.5%
Cash
$91.3M
Total Debt
$0
Free CF
$54.1M
52W Change
-59.5%
Annual Financials
Cash vs Debt
Where KYNB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KYNB finished 25.21% below its 150-day moving average ($7.06) and 27.67% below its 200-day moving average ($7.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KYNB overbought or oversold?
At the October 20, 2026 close, KYNB's RSI(14) was 25.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kyntra Bio, Inc. reports $91.3M in cash and $0 in total debt. The company generates $54.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Revenue has pulled back from $140.7M (2022) to $6.4M (2025), a 95% decline worth watching.
Investors considering Kyntra Bio, Inc. should weigh the typical risks associated with KYNB's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing KYNB.